CUBICIN® (daptomycin for injection)—from hospital to home

  • CUBICIN 4 mg/kg should be administered intravenously once every 24 hours for 7 to 14 days for cSSSI
  • CUBICIN 6 mg/kg should be administered once daily every 24 hours for 2 to 6 weeks for S. aureus bacteremia, including right-sided endocarditis
    • Continuing parenteral therapy in patients with complicated bacteremia for duration of therapy is strongly recommended1
Attributes for OPAT
Once-daily administration
In patients with severe renal impairment (CrCL <30 mL/min), administer CUBICIN once every 48 hours
2-minute IV injection (50 mg/mL) or 30-minute IV infusion (50 mL)
Can be given by peripheral line, midline, or peripherally inserted central catheter
No required drug-level monitoring. CPK levels should be monitored at least weekly
In patients with renal impairment, monitor renal function and CPK levels more than once weekly

Myopathy and rhabdomyolysis have been reported with CUBICIN use. Monitor for muscle pain or weakness, particularly of the distal extremities. Monitor creatine phosphokinase (CPK) levels weekly and more frequently in patients with CPK elevations while on CUBICIN treatment and in those who received recent prior or concomitant HMG-CoA reductase inhibitors. In patients with renal impairment, monitor renal function and CPK levels more than once weekly. Discontinue CUBICIN® (daptomycin for injection) in patients with unexplained signs and symptoms of myopathy with CPK levels >1,000 U/L (~5× ULN), and in patients without symptoms and CPK levels >2,000 U/L (≥10× ULN). In addition, consider temporarily suspending agents associated with rhabdomyolysis, such as HMG-CoA reductase inhibitors.